title: Stem cell transplantation post invasive fungal infection is a feasible task.
abstract: Between March 1997 and January 2002, 18 consecutive patients (18-47 years) with hematological malignancies and previous proven invasive fungal infection underwent stem cell transplantation (SCT) (10 matched sibling allograft, 6 autograft, and 2 haploidentical). All patients had full myeloablative conditioning. The fungal pathogens diagnosed were Aspergillus (14), Fusarium (2), Mucor (1), Exserohilum (1), and Candida (1), involving the lungs (15), sinuses (5), and liver (1). All patients were treated pre- and during transplant with systemic antifungal therapy. Eleven out of 18 (61%) patients survived the transplant. Only 1 of 5 patients who transplanted with an active fungal infection accompanied with active leukemia survived the transplant, compared with 10/13 (84%) survivals in patients who had no clinical and radiological signs of infection or active leukemia (P < 0.025). None of the autografted patients has died, compared with 7/12 allografted patients, of whom 5 underwent transplant with active hematological/active fungal disease. In only 3 patients was the cause of death reactivation of previous fungal infection. Both active fungal infection and active leukemia place patients at a very high risk for procedure-related mortality. Pre-transplant therapy of fungal infection, aiming to achieve a clinically undetectable state of infection, followed by an antifungal treatment during transplant may allow the SCT with no fungal reactivation in selected patients.
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, Technion, Haifa, Israel.
authors.forename: Irit
authors.initials: I
authors.lastname: Avivi
authors.forename: Ilana
authors.initials: I
authors.lastname: Oren
authors.forename: Nuhad
authors.initials: N
authors.lastname: Haddad
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Rowe
authors.forename: Eldad J
authors.initials: EJ
authors.lastname: Dann
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000401:mortality; D005240:Feasibility Studies; D005260:Female; D006098:Granulocytes / Q000637:transplantation; D006801:Humans; D007430:Intraoperative Care; D007938:Leukemia / Q000601:surgery*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000601:surgery*; D009181:Mycoses / Q000188:drug therapy* / Q000517:prevention & control* / Q000601:surgery; D012189:Retrospective Studies; D018570:Risk Assessment; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents